{
  "generated_at": "2026-02-03T11:03:52Z",
  "company_id": "immatics",
  "company_name": "Immatics",
  "kpis": {
    "assets_total": 8,
    "assets_with_trials": 2,
    "trials_total": 5,
    "trials_by_status": {
      "RECRUITING": 5
    },
    "assets_by_stage": {
      "Phase 1": 6,
      "Preclinical": 2
    }
  },
  "top_assets": [
    {
      "asset_id": 46,
      "asset_name": "anzu-cel",
      "highest_stage": "Phase 1",
      "linked_trials_count": 2,
      "indications": [
        {
          "indication": "2L melanoma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "2L melanoma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "2L melanoma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Solid cancers (in combination with mRNA-4203)",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Solid cancers (in combination with mRNA-4203)",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ],
      "last_change_at": null
    },
    {
      "asset_id": 47,
      "asset_name": "mRNA-4203",
      "highest_stage": "Phase 1",
      "linked_trials_count": 1,
      "indications": [
        {
          "indication": "Solid cancers (combo with anzu-cel / IMA203)",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Solid cancers (combo with anzu-cel / IMA203)",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Solid cancers (combo with anzu-cel / IMA203)",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ],
      "last_change_at": null
    },
    {
      "asset_id": 50,
      "asset_name": "IMA402 + ICI",
      "highest_stage": "Phase 1",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Melanoma, gynecologic cancers, other solid cancers (combo)",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Melanoma, gynecologic cancers, other solid cancers (combo)",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Melanoma, gynecologic cancers, other solid cancers (combo)",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ],
      "last_change_at": null
    },
    {
      "asset_id": 49,
      "asset_name": "IMA402",
      "highest_stage": "Phase 1",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Melanoma, gynecologic cancers, other solid cancers",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Melanoma, gynecologic cancers, other solid cancers",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Melanoma, gynecologic cancers, other solid cancers",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ],
      "last_change_at": null
    },
    {
      "asset_id": 51,
      "asset_name": "IMA401",
      "highest_stage": "Phase 1",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "HNSCC, sqNSCLC, other solid cancers",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "HNSCC, sqNSCLC, other solid cancers",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "HNSCC, sqNSCLC, other solid cancers",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ],
      "last_change_at": null
    },
    {
      "asset_id": 48,
      "asset_name": "IMA203CD8",
      "highest_stage": "Phase 1",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Gynecologic cancers; other solid cancers",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Gynecologic cancers; other solid cancers",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Gynecologic cancers; other solid cancers",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ],
      "last_change_at": null
    },
    {
      "asset_id": 53,
      "asset_name": "Undisclosed cell therapy",
      "highest_stage": "Preclinical",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Undisclosed",
          "stage": "Preclinical",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Undisclosed",
          "stage": "Preclinical",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Undisclosed",
          "stage": "Preclinical",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ],
      "last_change_at": null
    },
    {
      "asset_id": 52,
      "asset_name": "Undisclosed bispecific",
      "highest_stage": "Preclinical",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Undisclosed",
          "stage": "Preclinical",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Undisclosed",
          "stage": "Preclinical",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Undisclosed",
          "stage": "Preclinical",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ],
      "last_change_at": null
    }
  ],
  "recent_changes": [
    {
      "event_type": "trials_ingested",
      "created_at": null,
      "asset_id": null,
      "trial_id": null,
      "payload": {
        "trials_seen": 5,
        "inserted": 5,
        "updated": 0,
        "status_changed": 0,
        "bad_aliases": 0
      }
    },
    {
      "event_type": "trials_ingested",
      "created_at": null,
      "asset_id": null,
      "trial_id": null,
      "payload": {
        "trials_seen": 5,
        "inserted": 0,
        "updated": 5,
        "status_changed": 0,
        "bad_aliases": 0
      }
    },
    {
      "event_type": "trials_ingested",
      "created_at": null,
      "asset_id": null,
      "trial_id": null,
      "payload": {
        "trials_seen": 5,
        "inserted": 0,
        "updated": 5,
        "status_changed": 0,
        "bad_aliases": 0
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": null,
      "asset_id": null,
      "trial_id": 197,
      "payload": {
        "nct_id": "NCT06946225",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": null,
      "asset_id": null,
      "trial_id": 199,
      "payload": {
        "nct_id": "NCT06743126",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": null,
      "asset_id": null,
      "trial_id": 197,
      "payload": {
        "nct_id": "NCT06946225",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": null,
      "asset_id": null,
      "trial_id": 199,
      "payload": {
        "nct_id": "NCT06743126",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": null,
      "asset_id": null,
      "trial_id": 197,
      "payload": {
        "nct_id": "NCT06946225",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": null,
      "asset_id": null,
      "trial_id": 199,
      "payload": {
        "nct_id": "NCT06743126",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": null,
      "asset_id": null,
      "trial_id": 197,
      "payload": {
        "nct_id": "NCT06946225",
        "title": "A First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengine® IMA203-102)"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": null,
      "asset_id": null,
      "trial_id": 198,
      "payload": {
        "nct_id": "NCT03686124",
        "title": "Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": null,
      "asset_id": null,
      "trial_id": 199,
      "payload": {
        "nct_id": "NCT06743126",
        "title": "A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": null,
      "asset_id": null,
      "trial_id": 200,
      "payload": {
        "nct_id": "NCT05958121",
        "title": "A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER® Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors"
      }
    },
    {
      "event_type": "trial_added",
      "created_at": null,
      "asset_id": null,
      "trial_id": 201,
      "payload": {
        "nct_id": "NCT05359445",
        "title": "A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), as Monotherapy or in Combination With Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors."
      }
    },
    {
      "event_type": "pipeline_ingested",
      "created_at": null,
      "asset_id": null,
      "trial_id": null,
      "payload": {
        "pipeline_page": "https://immatics.com/our-pipeline/",
        "pipeline_image": "https://immatics.com/wp-content/uploads/2025/12/20251112_IMTX_pipeline_v3-scaled.png",
        "assets_seen": 8
      }
    },
    {
      "event_type": "pipeline_ingested",
      "created_at": null,
      "asset_id": null,
      "trial_id": null,
      "payload": {
        "pipeline_page": "https://immatics.com/our-pipeline/",
        "pipeline_image": "https://immatics.com/wp-content/uploads/2025/12/20251112_IMTX_pipeline_v3-scaled.png",
        "assets_seen": 8
      }
    },
    {
      "event_type": "pipeline_ingested",
      "created_at": null,
      "asset_id": null,
      "trial_id": null,
      "payload": {
        "pipeline_page": "https://immatics.com/our-pipeline/",
        "pipeline_image": "https://immatics.com/wp-content/uploads/2025/12/20251112_IMTX_pipeline_v3-scaled.png",
        "assets_seen": 8
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "asset_id": 46,
      "trial_id": null,
      "payload": {
        "asset": "anzu-cel",
        "indication": "Uveal melanoma",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "asset_id": 46,
      "trial_id": null,
      "payload": {
        "asset": "anzu-cel",
        "indication": "Solid cancers (in combination with mRNA-4203)",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "asset_id": 46,
      "trial_id": null,
      "payload": {
        "asset": "anzu-cel",
        "indication": "2L melanoma",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "asset_id": 47,
      "trial_id": null,
      "payload": {
        "asset": "mRNA-4203",
        "indication": "Solid cancers (combo with anzu-cel / IMA203)",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "asset_id": 48,
      "trial_id": null,
      "payload": {
        "asset": "IMA203CD8",
        "indication": "Gynecologic cancers; other solid cancers",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "asset_id": 49,
      "trial_id": null,
      "payload": {
        "asset": "IMA402",
        "indication": "Melanoma, gynecologic cancers, other solid cancers",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "asset_id": 50,
      "trial_id": null,
      "payload": {
        "asset": "IMA402 + ICI",
        "indication": "Melanoma, gynecologic cancers, other solid cancers (combo)",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "asset_id": 51,
      "trial_id": null,
      "payload": {
        "asset": "IMA401",
        "indication": "HNSCC, sqNSCLC, other solid cancers",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "asset_id": 52,
      "trial_id": null,
      "payload": {
        "asset": "Undisclosed bispecific",
        "indication": "Undisclosed",
        "stage": "Preclinical",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": null,
      "asset_id": 53,
      "trial_id": null,
      "payload": {
        "asset": "Undisclosed cell therapy",
        "indication": "Undisclosed",
        "stage": "Preclinical",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_added",
      "created_at": null,
      "asset_id": 46,
      "trial_id": null,
      "payload": {
        "asset": "anzu-cel"
      }
    },
    {
      "event_type": "asset_added",
      "created_at": null,
      "asset_id": 47,
      "trial_id": null,
      "payload": {
        "asset": "mRNA-4203"
      }
    },
    {
      "event_type": "asset_added",
      "created_at": null,
      "asset_id": 48,
      "trial_id": null,
      "payload": {
        "asset": "IMA203CD8"
      }
    },
    {
      "event_type": "asset_added",
      "created_at": null,
      "asset_id": 49,
      "trial_id": null,
      "payload": {
        "asset": "IMA402"
      }
    },
    {
      "event_type": "asset_added",
      "created_at": null,
      "asset_id": 50,
      "trial_id": null,
      "payload": {
        "asset": "IMA402 + ICI"
      }
    },
    {
      "event_type": "asset_added",
      "created_at": null,
      "asset_id": 51,
      "trial_id": null,
      "payload": {
        "asset": "IMA401"
      }
    },
    {
      "event_type": "asset_added",
      "created_at": null,
      "asset_id": 52,
      "trial_id": null,
      "payload": {
        "asset": "Undisclosed bispecific"
      }
    },
    {
      "event_type": "asset_added",
      "created_at": null,
      "asset_id": 53,
      "trial_id": null,
      "payload": {
        "asset": "Undisclosed cell therapy"
      }
    }
  ],
  "trials": [
    {
      "trial_id": 197,
      "nct_id": "NCT06946225",
      "title": "A First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengine® IMA203-102)",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-08",
      "linked_assets": [
        "anzu-cel",
        "mRNA-4203"
      ]
    },
    {
      "trial_id": 198,
      "nct_id": "NCT03686124",
      "title": "Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors",
      "overall_status": "RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2025-12-11",
      "linked_assets": []
    },
    {
      "trial_id": 199,
      "nct_id": "NCT06743126",
      "title": "A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2025-12-04",
      "linked_assets": [
        "anzu-cel"
      ]
    },
    {
      "trial_id": 200,
      "nct_id": "NCT05958121",
      "title": "A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER® Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors",
      "overall_status": "RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2025-11-18",
      "linked_assets": []
    },
    {
      "trial_id": 201,
      "nct_id": "NCT05359445",
      "title": "A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), as Monotherapy or in Combination With Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors.",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2025-09-09",
      "linked_assets": []
    }
  ]
}